Lymphoma is a potentially life threatening disease. The goal of this study was to investigate the therapeutic potential of a natural
triterpenoid,
Ganoderic acid A (GA-A) in controlling
lymphoma growth both in vitro and in vivo. Here, we show that GA-A treatment induces
caspase-dependent apoptotic cell death characterized by a dose-dependent increase in active
caspases 9 and 3, up-regulation of pro-apoptotic BIM and BAX
proteins, and a subsequent loss of mitochondrial membrane potential with release of
cytochrome c. In addition to GA-A's anti-growth activity, we show that lower doses of GA-A enhance HLA class II-mediated
antigen (Ag) presentation and CD4+ T cell recognition of
lymphoma cells in vitro. The therapeutic relevance of GA-A treatment was also tested in vivo using the EL4 syngeneic mouse model of metastatic
lymphoma. GA-A-treatment significantly prolonged survival of EL4 challenged mice and decreased
tumor metastasis to the liver, an outcome accompanied by a marked down-regulation of STAT3 phosphorylation, reduction myeloid-derived suppressor cells (MDSCs), and enhancement of cytotoxic CD8+ T cells in the host. Thus, GA-A not only selectively induces apoptosis in
lymphoma cells, but also enhances cell-mediated immune responses by attenuating MDSCs, and elevating Ag presentation and T cell recognition. The demonstrated therapeutic benefit indicates that GA-A is a candidate for future
drug design for the treatment of
lymphoma.